N/A
Manufactured by CMP Pharma, Inc.
29,971 FDA adverse event reports analyzed
Last updated: 2026-04-14
ISONIAZID is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by CMP Pharma, Inc.. The most commonly reported adverse reactions for ISONIAZID include DRUG INEFFECTIVE, PYREXIA, DRUG INTERACTION, NAUSEA, DRUG-INDUCED LIVER INJURY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ISONIAZID.
Out of 15,643 classified reports for ISONIAZID:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 29,971 FDA FAERS reports that mention ISONIAZID. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, PYREXIA, DRUG INTERACTION, NAUSEA, DRUG-INDUCED LIVER INJURY, OFF LABEL USE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list CMP Pharma, Inc. in connection with ISONIAZID. Always verify the specific product and NDC with your pharmacist.